Abstract：Objective: To analyze the relationship between the serum level of Sestrin2 and the severity and prognosis of acute ischemic stroke (AIS). Methods: A total of 98 patients with AIS who were admitted to the hospital during the period from January 2017 to January 2018 were included in the case group, and 40 persons who underwent physical examination in the same period were included in the control group. Serum Sestrin2 levels were determined by double-antibody sandwich enzyme-linked immunosorbent assay (ELISA). According to the National Institute of Health Stroke Scale (NIHSS), the patients were divided into mild, moderate and severe three subgroups. According to the modified Rankin (mRS) score at 3 months after discharge, the patients were divided into good prognosis group and poor prognosis group. The serum Sestrin2 levels were compared between subgroups. Results: The level of serum Sestrin2 in the case group was significantly higher than that in the control group [(13.90±2.54) ng/mL vs (11.76±1.41) ng/mL] (P<0.05). There were significant differences in serum Sestrin2 levels among the mild, moderate and severe groups (P<0.05), but there was no significant difference in the serum Sestrin2 level between the good prognosis group and the poor prognosis group [(13.69±1.95) ng/mL vs (14.60±2.38) ng/mL] (P>0.05). The serum Sestrin2 level was positively correlated with the NIHSS score (P<0.05) but not correlated with the mRS score (P>0.05). Conclusion: The level of serum Sestrin2 in patients with AIS is related to the severity of the disease, but there is no significant correlation with the prognosis.
2019, Vol. 25 
冀公网安备13080202000677号